Лечение IgG4-связанного заболевания
https://doi.org/10.14412/1995-4484-2016-352-360
Аннотация
IgG4-связанное заболевание (IgG4-СЗ) – это фибровоспалительная патология, характеризующаяся возникновением в различных органах опухолеподобных очагов с уникальной гистологической картиной (муароподобный фиброз, выраженный лимфоплазмоцитарный инфильтрат с большим количеством IgG4+ плазмоцитов, облитерирующий флебит) и повышением уровня IgG4 в сыворотке крови большинства пациентов. Терапией первой линии являются глюкокортикоиды в стартовой дозе 0,6 мг/кг/сут (в пересчете на преднизолон), однако такое лечение сопряжено со множеством неблагоприятных реакций и высоким уровнем рецидивов. В статье приводится обзор имеющейся на сегодняшний день литературы по лечению IgG4-СЗ; особое внимание уделено описанию терапии глюкокортикоидами и ритуксимабом.
Об авторах
Е. В. Сокол
ФГБНУ Научно-исследовательский институт ревматологии им. В.А. Насоновой
Россия
115522 Москва, Каширское шоссе, 34А
Россия
115522 Москва, Каширское шоссе, 34А
В. И. Васильев
ФГБНУ Научно-исследовательский институт ревматологии им. В.А. Насоновой
Россия
115522 Москва, Каширское шоссе, 34А
Россия
115522 Москва, Каширское шоссе, 34А
Список литературы
1. Deshpande V, Zen Y, Chan JK, et al. Consensus statement on the pathology of IgG4-related disease. Mod Pathol. 2012 Sep;25(9):1181-92. doi: 10.1038/modpathol.2012.72
2. Umehara H, Okazaki K, Masaki Y, et al. Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011. Mod Rheumatol. 2012 Feb;22(1):21-30. doi: 10.3109/s10165-011-0571-z
3. Седышев СХ, Васильев ВИ, Ковригина АМ, Насонов ЕЛ. IgG4-связанное системное заболевание. Современный взгляд на «старые» болезни. Научно-практическая ревматология. 2012;50(5):64-72 [Sedyshev SK, Vasiliev VI, Kovriguina AM, Nasonov EL. IgG4-linked systemic disease. modern outlook on «old» disease. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2012;50(5):64-72 (In Russ.)]. doi: 10.14412/1995-4484-2012-1184
4. Khosroshahi A, Stone JH. Treatment approaches to IgG4-related systemic disease. Curr Opin Rheumatol. 2011 Jan;23(1):67-71. doi: 10.1097/BOR.0b013e328341a240
5. Shimosegawa T, Chari ST, Frulloni L, et al. International consensus diagnostic criteria for autoimmune pancreatitis: guidelines of the International Association of Pancreatology. Pancreas. 2011 Apr;40(3):352-8. doi: 10.1097/MPA.0b013e3182142fd2
6. Moon SH, Kim MH, Park DH, et al. Is a 2-week steroid trial after initial negative investigation for malignancy useful in differentiating autoimmune pancreatitis from pancreatic cancer? A prospective outcome study. Gut. 2008 Dec;57(12):1704-12. doi: 10.1136/gut.2008.150979
7. Otsuki M, Chung JB, Okazaki K et al. Asian diagnostic criteria for autoimmune pancreatitis: consensus of the Japan-Korea Symposium on Autoimmune Pancreatitis. J Gastroenterol. 2008;43(6):403-8. doi: 10.1007/s00535-008-2205-6
8. Chari ST. Diagnosis of autoimmune pancreatitis using its five cardinal features: introducing the Mayo Clinic's HISORt criteria. J Gastroenterol. 2007 May;42 Suppl 18:39-41. doi: 10.1007/s00535-007-2046-8
9. Masaki Y, Shimizu H, Sato Nakamura T, et al. IgG4-related disease: diagnostic methods and therapeutic strategies in Japan. J Clin Exp Hematop. 2014;54(2):95-101. doi: 10.3960/jslrt.54.95
10. Shimizu Y, Yamamoto M, Naishiro Y, et al. Necessity of early intervention for IgG4-related disease – delayed treatment induces fibrosis progression. Rheumatology (Oxford). 2013 Apr;52(4):679-83. doi: 10.1093/rheumatology/kes358
11. Kubota K, Watanaba S, Uchiyama T, et al. Factors predictive of relapse and spontaneous remission of autoimmune pancreatitis patients treated/not treated with corticosteroids. J Gastroenterol. 2011 Jun;46(6):834-42. doi: 10.1007/s00535-011-0393-y
12. Kamisawa T, Okazaki K, Kawa S, et al. Amendment of the Japanese Consensus Guidelines for Autoimmune Pancreatitis, 2013 III. Treatment and prognosis of autoimmune pancreatitis. J Gastroenterol. 2014 Jun;49(6):961-70. doi: 10.1007/s00535-014-0945-z
13. Kamisawa T, Okamoto A. Prognosis of autoimmune pancreatitis. J Gastroenterol. 2007 May;42 Suppl 18:59-62. doi: 10.1007/s00535-007-2052-x
14. Ozden I, Dizdaroglu F, Poyanli A, et al. Spontaneous regression of a pancreatic head mass and biliary obstruction due to autoimmune pancreatitis. Pancreatology. 2005;5(2-3):300-3. doi: 10.1159/000085287
15. Miura H, Miyachi Y. IgG4-related retroperitoneal fibrosis and sclerosing cholangitis independent of autoimmune pancreatitis. A recurrent case after a 5-year history of spontaneous remission. JOP. 2009 Jul 6;10(4):432-7.
16. Ghazale A, Chari ST, Zhang L, et al. Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy. Gastroenterology. 2008 Mar;134(3):706-15. doi: 10.1053/j.gastro.2007.12.009
17. Saeki T, Kawano M, Mizushima I, et al. The clinical course of patients with IgG4-related kidney disease. Kidney Int. 2013 Oct;84(4):826-33. doi: 10.1038/ki.2013.191
18. Kim HM, Chung MJ, Chung JB. Remission and relapse of autoimmune pancreatitis: focusing on corticosteroid treatment. Pancreas. 2010 Jul;39(5):555-60. doi: 10.1097/MPA.0b013e3181c8b4a5
19. Hart PA, Topazian MP, Witzig TE, et al. Treatment of relapsing autoimmune pancreatitis with immunomodulators and rituximab: the Mayo Clinic experience. Gut. 2013 Nov;62(11):1607-15. doi: 10.1136/gutjnl-2012-302886
20. Carruthers MN, Topazian MP, Khosroshahi A, et al. Rituximab for IgG4-related disease: a prospective, open-label trial. Ann Rheum Dis. 2015 Jun;74(6):1171-7. doi: 10.1136/annrheumdis-2014-206605
21. Hirano K, Tada M, Isayama H, et al. Long-term prognosis of autoimmune pancreatitis with and without corticosteroid treatment. Gut. 2007 Dec;56(12):1719-24. doi: 10.1136/gut.2006.115246
22. Kamisawa T, Shimosegawa T, Okazaki K, et al. Standard steroid treatment for autoimmune pancreatitis. Gut. 2009 Nov;58(11):1504-7. doi: 10.1136/gut.2008.172908
23. Васильев ВИ, Логвиненко ОА, Седышев СХ и др. IgG4-связанное заболевание. Клинические наблюдения. Научно-практическая ревматология. 2013;51(5):578-85 [Vasilyev VI, Logvinenko OA, Sedyshev SKh, et al. IgG4-related disease. Clinical notes. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2013;51(5):578-85 (In Russ.)]. doi: 10.14412/1995-4484-2013-1552
24. Khosroshahi A, Wallace ZS, Crowe JL, et al. International Consensus Guidance Statement on the Management and Treatment of IgG4-Related Disease. Arthritis Rheum. 2015 Jul;67(7):1688-99. doi: 10.1002/art.39132
25. Ghazale A, Chari ST. Optimising corticosteroid treatment for autoimmune pancreatitis. Gut. 2007 Dec;56(12):1650-2. doi: 10.1136/gut.2007.129833
26. Hart PA, Kamisawa T, Brugge WR, et al. Long-term outcomes of autoimmune pancreatitis: a multicentre, international analysis. Gut. 2013 Dec;62(12):1771-6. doi: 10.1136/gutjnl-2012-303617
27. Sandanayake NS, Church NI, Chapman MH, et al. Presentation and management of post-treatment relapse in autoimmune pancreatitis/immunoglobulin G4-associated cholangitis. Clin Gastroenterol Hepatol. 2009 Oct;7(10):1089-96. doi: 10.1016/j.cgh.2009.03.021
28. Buechter M, Klein CG, Kloeters C, et al. Tacrolimus as a reasonable alternative in a patient with steroid-dependent and thiopurine-refractory autoimmune pancreatitis with IgG4- associated cholangitis. Z Gastroenterol. 2014 Jun;52(6):564-8. doi: 10.1055/s-0034-1366331
29. Topazian M, Witzig TE, Smyrk TC, et al. Rituximab therapy for refractory biliary strictures in immunoglobulin G4-associated cholangitis. Clin Gastroenterol Hepatol. 2008 Mar;6(3):364-6. doi: 10.1016/j.cgh.2007.12.020
30. Della-Torre E, Campochiaro C, Bozzolo EP, et al. Methotrexate for maintenance of remission in IgG4-related disease. Rheumatology (Oxford). 2015 Oct; 54(10):1934-6. doi: 10.1093/rheumatology/kev244
31. Khan ML, Colby TV, Viggiano RW, et al. Treatment with bortezomib of a patient having hyper IgG4 disease. Clin Lymphoma Myeloma Leuk. 2010 Jun;10(3):217-9. doi: 10.3816/CLML.2010.n.034
32. Miyata KN, Kihira H, Haneda M, et al. IgG4-related tubulointerstitial nephritis associated with membranous nephropathy in two patients: remission after administering a combination of steroid and mizoribine. Case Rep Nephrol. 2014;2014:678538. doi: 10.1155/2014/678538
33. Vaglio A, Palmisano A, Alberici F, et al. Prednisone versus tamoxifen in patients with idiopathic retroperitoneal fibrosis: an openlabel randomised controlled trial. Lancet. 2011 Jul 23;378(9788):338-46. doi: 10.1016/S0140-6736(11)60934-3
34. Tomiyama T, Uchida K, Matsushita M, et al. Comparison of steroid pulse therapy and conventional oral steroid therapy as initial treatment for autoimmune pancreatitis. J Gastroenterol. 2011 May;46(5):696-704. doi: 10.1007/s00535-010-0361-y
35. Ko SB, Mizuno N, Yatabe Y, et al. Corticosteroids correct aberrant CFTR localization in the duct and regenerate acinar cells in autoimmune pancreatitis. Gastroenterology. 2010 May;138(5):1988-96. doi: 10.1053/j.gastro.2010.01.001
36. Hirano K, Shiratori Y, Komatsu Y, et al. Involvement of the biliary system in autoimmune pancreatitis: a follow-up study. Clin Gastroenterol Hepatol. 2003 Nov;1(6):453-64. doi: 10.1016/S1542-3565(03)00221-0
37. Kanno A, Masamune A, Okazaki K, et al. Nationwide epidemiological survey of autoimmune pancreatitis in Japan in 2011. Pancreas. 2015 May;44(4):535-9. doi: 10.1097/MPA.0000000000000325
38. Hirano K, Tada M, Isayama H, et al. Indication for steroid therapy in autoimmune pancreatitis patients without obstructive jaundice. Abstract. 2nd International symposium on IgG4-RD and associated conditions. 2014.
39. Chari ST, Smyrk TC, Levy MJ, et al. Diagnosis of autoimmune pancreatitis: the Mayo Clinic experience. Clin Gastroenterol Hepatol. 2006 Aug;4(8):1010-6. doi: 10.1016/j.cgh.2006.05.017
40. Okazaki K, Kawa S, Kamisawa T, et al. Amendment of the Japanese Consensus Guidelines for Autoimmune Pancreatitis, 2013 I. Concept and diagnosis of autoimmune pancreatitis. J Gastroenterol. 2014 Apr;49(4):567-88. doi: 10.1007/s00535-014-0942-2
41. Boumpas DT, Chrousos GP, Wilder RL, et al. Glucocorticoid therapy for immune-mediated diseases: basic and clinical correlates. Ann Intern Med. 1993 Dec 15;119(12):1198-208. doi: 10.7326/0003-4819-119-12-199312150-00007
42. Matsushita M, Yamashina M, Ikeura T, et al. Effective steroid pulse therapy for the biliary stenosis caused by autoimmune pancreatitis. Am J Gastroenterol. 2007;102:220-1.
43. Khosroshahi A, Carruthers MN, Stone JH, et al. Rethinking Ormond's disease: «idiopathic» retroperitoneal fibrosis in the era of IgG4-related disease. Medicine (Baltimore). 2013 Mar;92(2):82-91. doi: 10.1097/MD.0b013e318289610f
44. Kamisawa T, Egawa N, Inokuma S, et al. Pancreatic endocrine and exocrine function and salivary gland function in autoimmune pancreatitis before and after steroid therapy. Pancreas. 2003 Oct;27(3):235-8. doi: 10.1097/00006676-200310000-00007
45. Nishimori I, Tamakoshi A, Kawa S, et al. Influence of steroid therapy on the course of diabetes mellitus in patients with autoimmune pancreatitis: findings from a nationwide survey in Japan. Pancreas. 2006 Apr;32(3):244-8. doi: 10.1097/01.mpa.0000202950.02988.07
46. Uchida K, Yazumi S, Nishio A, et al. Long-term outcome of autoimmune pancreatitis. J Gastroenterol. 2009;44(7):726-32. doi: 10.1007/s00535-009-0049-3
47. Kamisawa T, Egawa N, Nakajima H, et al. Extrapancreatic lesions in autoimmune pancreatitis. J Clin Gastroenterol. 2005 Nov-Dec;39(10):904-7. doi: 10.1097/01.mcg.0000180629.77066.6c
48. Wu A, Andrew NH, Tsirbas A, et al. Rituximab for the treatment of IgG4-related orbital disease: experience from five cases. Eye (Lond). 2015 Jan;29(1):122-8. doi: 10.1038/eye.2014.251
49. Khosroshahi A, Bloch DB, Deshpande V, et al. Rituximab therapy leads to rapid decline of serum IgG4 levels and prompt clinical improvement in IgG4-related systemic disease. Arthritis Rheum. 2010 Jun;62(6):1755-62. doi: 10.1002/art.27435
50. Насонов ЕЛ, редактор. Анти-В-клеточная терапия в ревматологии: фокус на ритуксимаб. Москва: ИМА-ПРЕСС; 2012. 344 с. [Nasonov EL, editor. Anti-B-kletochnaya terapiya v revmatologii: fokus na rituksimab [Anti-B-cell therapy in rheumatology: Focus on rituximab]. Moscow: IMA-PRESS; 2012. 344 p.].
51. Zambruno G, Borradori L. Rituximab immunotherapy in pemphigus: therapeutic effects beyond B-cell depletion. J Invest Dermatol. 2008 Dec;128(12):2745-7. doi: 10.1038/jid.2008.330
52. Murakami J, Matsui S, Ishizawa S, et al. Recurrence of IgG4-related disease following treatment with rituximab. Mod Rheumatol. 2013 Nov;23(6):1226-30. doi: 10.3109/s10165-012-0738-2
53. Yamamoto M, Awakawa T, Takahashi H. Is rituximab effective for IgG4-related disease in the long term? Experience of cases treated with rituximab for 4 years. Ann Rheum Dis. 2015 Aug;74(8):e46. doi: 10.1136/annrheumdis-2015-207625
54. Khosroshahi A, Carruthers MN, Deshpande V, et al. Rituximab for the treatment of IgG4-related disease: lessons from 10 consecutive patients. Medicine (Baltimore). 2012 Jan;91(1):57-66. doi: 10.1097/MD.0b013e3182431ef6
55. Васильев ВИ, Пальшина СГ, Симонова МВ и др. Первый опыт использования ритуксимаба в терапии болезни Микулича. Терапевтический архив. 2010;82(6):62-6 [Vasil’ev VI, Pal’shina SG, Simonova MV, et al. The first experience with rituximab in the treatment of Mikulic’s disease. Terapevticheskii Arkhiv. 2010;82(6):62-6 (In Russ.)].
56. Grimm KE, Bakke A, O'Malley DP. Abnormal expression of CD20 on IgG4 plasma cells associated with IgG4-related lymphadenopathy. Arch Pathol Lab Med. 2013 Sep;137(9):1282-5. doi: 10.5858/arpa.2012-0466-OA
57. Della-Torre E, Feeney E, Deshpande V, et al. B-cell depletion attenuates serological biomarkers of fibrosis and myofibroblast activation in IgG4-related disease. Ann Rheum Dis. 2015 Dec;74(12):2236-43. doi: 10.1136/annrheumdis-2014-205799
58. Седышев СХ, Васильев ВИ, Ковригина АМ и др. Заболевание, связанное с IgG4: характеристика группы больных и терапия ритуксимабом. Терапевтический архив. 2013;85(2):48-53 [Sedyshev SKh, Vasil'ev VI, Kovrigina AM, et al. The disease is associated with IgG4: the characteristic group of patients and rituximab therapy. Terapevticheskii arkhiv. 2013;85(2):48-53 (In Russ.)].
Рецензия
Для цитирования:
Сокол Е.В., Васильев В.И. Лечение IgG4-связанного заболевания. Научно-практическая ревматология. 2016;54(3):352-360. https://doi.org/10.14412/1995-4484-2016-352-360
For citation:
Sokol E.V., Vasilyev V.I. TREATMENT OF IgG4-RELATED DISEASE. Rheumatology Science and Practice. 2016;54(3):352-360. (In Russ.) https://doi.org/10.14412/1995-4484-2016-352-360
Просмотров:
1369
Послать статью по эл. почте 